Upward Trend In Major Psychedelic Compound-Based Research & Development Stocks Continue

There are 6 constituents in our munKNEE Psychedelic Drug Stocks Index and 5 of them advanced this week and are now all up MTD. Below are the details in descending order of performance.

1. Seelos (SEEL): UP 7.6% this week; UP 6.5% MTD
   • is primarily focused on the use of ketamine*. Go here for much more extensive information on Ketamine.
   • Read: Seelos Addressing Significant And Unmet Needs In Rare Psychiatric And Movement Disorders
2. Compass Pathways (CMPS): UP 2.7% this week; UP 9.7% MTD
   • is primarily focused on the use of psilocybin* (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
3. Atai (ATAI); UP 2.3% this week; No Change MTD
   • is primarily focused on the use of ketamine*, DMT* and ibogaine*.  Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
   • Read: Atai Life Sciences: Long On Money; Short On Success
4. Mind Medicine (MNMD): UP 1.4% this week; UP 4.8% MTD
   • is primarily focused on the use of LSD* and MNMA*. Go here for much more extensive information on LSD and  here for much more extensive information on MNMA.
   • Read: MindMed: Researching LSD And MNMA To Treat Neurological Diseases
5. Incannex Healthcare (IXHL): No Change this week; UP 2.1% MTD
   • is researching and developing therapies and products with the world's largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
   • Read: Incannex Healthcare Has World's Largest Pipeline Of Psychedelic Products
6. GH Research (GHRS): DOWN 1.6% this week; UP 8.6% MTD
7. • is primarily focused on the use of mebufotenin*, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine but is better known by its nickname, “The Toad”,
   • Read: GH Resources: Focus On Treatment-Resistant Depression Paying Off 

*Read 10 Psychedelic Substances And The 36 Companies Researching Them for a description of each of the psychedelic-based compounds mentioned in this article.

Summary:

The munKNEE Psychedelic Drug Stocks Index is up 0.6% this week and is now up 7.3% MTD.

If you are interested in this category of clinical-stage psychedelic compound-based stocks consider the  AdvisorShares Psychedelic ETF (PSIL) which consists of 23 such stocks - but keep in mind that the vast majority have market capitalizations of $50M or less (i.e. are nano-caps). It is up 2.2% MTD and is now up 8.2% MTD.

---

More By This Author:

Increase In Beyond Meat's Short Interest Percentage Propels Plant-Based Food Stocks Index
Majority of American MSOs Down MTD, Again, Led By Trulieve
Artificial Intelligence (AI) Stocks: In A Bubble Or Not?